Cargando…

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

SIMPLE SUMMARY: Growth factors are hormone-like molecules able to promote division and migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor growth and metastasis. Here we review the epidermal growth factor (EGF), which controls epithelial cells, the precursors of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uribe, Mary Luz, Marrocco, Ilaria, Yarden, Yosef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197917/ https://www.ncbi.nlm.nih.gov/pubmed/34206026 http://dx.doi.org/10.3390/cancers13112748

Ejemplares similares

Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators
por: Marrocco, Ilaria, et al.
Publicado: (2023)

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
por: Marrocco, Ilaria, et al.
Publicado: (2021)

Roles for growth factors and mutations in metastatic dissemination
por: Nataraj, Nishanth Belugali, et al.
Publicado: (2021)

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
por: Mancini, Maicol, et al.
Publicado: (2017)

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
por: Chhouri, Houssein, et al.
Publicado: (2023)

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
por: Romaniello, Donatella, et al.
Publicado: (2020)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
por: Yu, Tao, et al.
Publicado: (2020)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab
por: Marrocco, Ilaria, et al.
Publicado: (2023)

Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
por: Amit, Ido, et al.
Publicado: (2007)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
por: Santoni-Rugiu, Eric, et al.
Publicado: (2019)

The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors
por: Schneider, Marlon R., et al.
Publicado: (2015)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
por: Sun, Ruizhu, et al.
Publicado: (2022)

Mechanisms of EGFR Resistance in Glioblastoma
por: Pan, Peter C., et al.
Publicado: (2020)

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
por: Leto, Simonetta M., et al.
Publicado: (2014)

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
por: Liu, Bing, et al.
Publicado: (2021)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
por: Li, Qing-Hai, et al.
Publicado: (2020)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
por: Choi, Yu-ra, et al.
Publicado: (2022)

The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them
por: Rocco, Danilo, et al.
Publicado: (2022)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu, Danlei, et al.
Publicado: (2021)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
por: Wu, Wen-Shuo, et al.
Publicado: (2014)

A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy
por: Gelfo, Valerio, et al.
Publicado: (2018)

A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma
por: Wang, Weidong, et al.
Publicado: (2023)

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
por: Wu, Shang-Gin, et al.
Publicado: (2018)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
por: Gelfo, Valerio, et al.
Publicado: (2016)

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
por: Diaz, Luis A., et al.
Publicado: (2012)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
por: Li, Ling, et al.
Publicado: (2020)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms
por: Aldonza, Mark Borris D., et al.
Publicado: (2020)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2vesit68gva8j0mko9t33rfje1